title: Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
abstract: Introduction Conjugated estrogens/bazedoxifene (CE/BZA) relieves menopausal symptoms and increases bone mineral density (BMD). Objective To evaluate CE/BZA in a Latin American subpopulation from randomized, double-blind, phase-3, multinational trials. Methods Safety data were pooled from three trials from non-hysterectomized postmenopausal Latin American women assigned to CE 0.45 mg/BZA 20 mg (n = 227), CE 0.625 mg/BZA 20 mg (n = 222), or placebo (n = 193). Efficacy outcomes from one study included changes in hot flush frequency at week 12 in women with at least seven moderate/severe hot flushes/day or 50/week at baseline (n = 39), and from baseline to month 12 for BMD (n = 381) and genitourinary syndrome of menopause (GSM) (women with baseline GSM; n = 189). Results At week 12, women taking CE/BZA had four to five fewer moderate/severe hot flushes/day vs. placebo. At month 12, percentage changes in BMD with CE 0.45 mg/BZA 20 mg, CE 0.625 mg/BZA 20 mg, and placebo were 1.2%, 1.6%, and -1.1% for lumbar spine and 1.1%, 1.2%, and -0.3% for total hip. GSM improved with treatment (percentage superficial cells: 4.5, 7.4, vs. 2.0; percentage parabasal cells: -9.3, -27.8 vs. 2.8). There were no new/unexpected safety trends. Conclusion CE/BZA improved vasomotor symptoms, GSM, and BMD in Latin American women, with efficacy/safety similar to the global population.
authors.affiliation: a Palacios Institute of Women's Health , Madrid , Spain ;
authors.forename: S
authors.initials: S
authors.lastname: Palacios
authors.affiliation: b Pfizer Inc, Bosques de las Lomas , Mexico ;
authors.forename: L
authors.initials: L
authors.lastname: Arias
authors.affiliation: c Pfizer Inc, Collegeville , PA , USA.
authors.forename: J
authors.initials: J
authors.lastname: Lavenberg
authors.affiliation: c Pfizer Inc, Collegeville , PA , USA.
authors.forename: K
authors.initials: K
authors.lastname: Pan
authors.affiliation: c Pfizer Inc, Collegeville , PA , USA.
authors.forename: S
authors.initials: S
authors.lastname: Mirkin
authors.affiliation: c Pfizer Inc, Collegeville , PA , USA.
authors.forename: B S
authors.initials: BS
authors.lastname: Komm
mesh_terms: D000328:Adult; D000368:Aged; D001284:Atrophy / Q000188:drug therapy; D015992:Body Mass Index; D015519:Bone Density; D004311:Double-Blind Method; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007843:Latin America; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage* / Q000009:adverse effects; D014621:Vagina / Q000473:pathology; D014844:Vulva / Q000473:pathology
chemical_list: D004966:Estrogens, Conjugated (USP); D007211:Indoles; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; C447119:bazedoxifene
keywords: Latin America; TSEC; conjugated estrogens/bazedoxifene; genitourinary syndrome of menopause; hot flashes; hot flushes; menopause; osteoporosis; vulvar vaginal atrophy